ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Education
Visit Zacks' Education section for investing guides and other free resources to make you a better investor.

Quote:

Search for Ticker

Free Membership

Search:

CYBX: Cyberonics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

CYBERONICS INC (NASD)
CYBX	17.60	1.15	(6.99%)	Vol. 358,408	16:00 ET

Cyberonics, Inc. was founded to design, develop and market medical devices for the treatment of epilepsy and other debilitating neurological disorders using a therapy, vagus nerve stimulation. The company's initial target market is epilepsy, the world's second most prevalent neurological disorder, which is characterized by seizures. Vagus nerve stimulation with the Cyberonics NCP System was approved for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents with medically refractory partial onset seizures. (PRESS RELEASE)

General Information

CYBERONICS INC

100 Cyberonics Blvd Cyberonics Building Houston, TX 77058-2072 Phone: 281 228-7200 Fax: 281 218-9332 Web: www.cyberonics.com Email: ir@cyberonics.com

Industry	MED INSTRUMENTS
Sector:	Medical

Fiscal Year End	April
Last Reported Quarter	10/31/09
Next EPS Date	02/17/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	16.45
52 Week High	18.29
52 Week Low	11.54
Beta	0.56
20 Day Moving Average	145,467.66
Target Price Consensus	18.65

% Price Change
4 Week	18.68
12 Week	16.63
YTD	6.22

% Price Change Relative to S&P 500
4 Week	17.40
12 Week	9.96
YTD	-12.09

Share Information
Shares Outstanding (millions)	27.75
Market Capitalization (millions)	488.31
Short Ratio	19.91
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.20
Current Year EPS Consensus Estimate	0.88
Estimated Long-Term EPS Growth Rate	27.30
Next EPS Report Date	02/17/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.50
30 Days Ago	2.50
60 Days Ago	2.50
90 Days Ago	2.67

Fundamental Ratios

P/E
Current FY Estimate:	19.92
Trailing 12 Months:	19.13
PEG Ratio	0.69

EPS Growth
vs. Previous Year	128.57%
vs. Previous Quarter	39.13%

Sales Growth
vs. Previous Year	13.01%
vs. Previous Quarter:	5.76%

Price Ratios
Price/Book	5.58
Price/Cash Flow	27.79
Price / Sales	3.19

ROE
10/31/09	66.32
07/31/09	109.92
04/30/09	170.23

ROA
10/31/09	22.72
07/31/09	19.85
04/30/09	13.34

Current Ratio
10/31/09	6.15
07/31/09	5.86
04/30/09	5.93

Quick Ratio
10/31/09	5.36
07/31/09	5.05
04/30/09	5.20

Operating Margin
10/31/09	17.59
07/31/09	14.56
04/30/09	11.00

Net Margin
10/31/09	22.59
07/31/09	22.49
04/30/09	19.12

Pre-Tax Margin
10/31/09	22.59
07/31/09	22.49
04/30/09	19.12

Book Value
10/31/09	3.15
07/31/09	1.28
04/30/09	0.89

Inventory Turnover
10/31/09	1.56
07/31/09	1.61
04/30/09	1.60

Debt-to-Equity
10/31/09	0.45
07/31/09	1.34
04/30/09	2.55

Debt to Capital
10/31/09	30.95
07/31/09	57.25
04/30/09	71.86


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research